ASHP -- BETHESDA, MD 29 May 2009—FDA’s recent approval of a reformulated version of Solvay Pharmaceutical Inc.'s delayed-release pancrelipase product, Creon, gives pharmacists who are active in the cystic fibrosis community something new—a pancreatic enzyme product that has passed regulatory muster.
